Louis Benevento, MD
Internal Medicine · Las Cruces, NMNPI 1063445666
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $613 and has fallen 61.7% since, to $235 in 2025. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$397
- Boehringer Ingelheim$373
- Novo Nordisk$356
- Insulet Corporation$309
- Bayer$229
- GSK$177
- plus $604 from 17 others
What the payments were for
- Food & beverage$2,434100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 23 | $397 |
| Boehringer Ingelheim | 18 | $373 |
| Novo Nordisk | 28 | $356 |
| Insulet Corporation | 12 | $309 |
| Bayer | 12 | $229 |
| GSK | 10 | $177 |
| AbbVie | 4 | $94 |
| Medtronic(2 entities) | 5 | $76 |
| AstraZeneca | 5 | $72 |
| Mylan Specialty L.p. | 3 | $59 |
| Abbott | 2 | $45 |
| Amgen | 2 | $38 |
| Recordati_rare_diseases_inc. | 1 | $31 |
| Tactile Systems Technology Inc | 2 | $29 |
| Lundbeck LLC | 1 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| BETA Bionics, Inc. | 1 | $17 |
| BD | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
| Merck | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$2,446 in reported general payments places this provider in the 90th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $45,904 |
| MounjaroTirzepatide | 19 | $26,682 |
| OzempicSemaglutide | 19 | $26,413 |
| JanuviaSitagliptin Phosphate | 14 | $22,406 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,197 |
| Losartan Potassium | 233 | $3,225 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,496 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $2,020 |
| Atorvastatin Calcium | 179 | $1,982 |
| Levothyroxine Sodium | 148 | $1,963 |
| Amlodipine Besylate | 195 | $1,902 |
| Lisinopril | 157 | $1,869 |
| Omeprazole | 85 | $1,595 |
| Gabapentin | 110 | $1,496 |
| Tamsulosin Hcl | 92 | $1,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $45,90442 claims |
| Lilly USA, LLCMounjaro | $397 | $26,68219 claims |
| Novo NordiskOzempic | $356 | $26,41319 claims |
| MerckJanuvia | $13 | $22,40614 claims |
| AbbVieSynthroid | $94 | $1,06024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Las Cruces
- Ann MercerLas Cruces$6K
- Sangeeth PaiLas Cruces$4K
- Syed AhmedLas Cruces$3K
- Azhar ZahirLas Cruces$3K
- Talha KhanLas Cruces$3K
- Jobin PhiliposeLas Cruces$2K
- Edna JuarezLas Cruces$2K
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.